Cytomegalovirus retinitis in the era of combined highly active antiretroviral therapy

Ophthalmology Clinics of North America

Volumn 15, Issue 4, 2002, Pages 529-536

  See, Robert F ^a   Rao, Narsing A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; FOSCARNET; GANCICLOVIR; VALGANCICLOVIR;

CLINICAL FEATURE; CLINICAL TRIAL; CYTOMEGALOVIRUS; GENITAL ULCER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; MALAISE; NEPHROTOXICITY; NEUTROPENIA; PARESTHESIA; PATHOGENESIS; PRIORITY JOURNAL; RETINITIS; REVIEW; UVEITIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS RETINITIS; HUMANS;

EID: 0036951518     PISSN: 08961549     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-1549(02)00048-2     Document Type: Review

References (66)

1. Baril L, Jouan M, Agher R, Cambau E, Caumes E, Bricaire F, et al. Impact of highly active antiretroviral therapy on onset of Mycobacterium avium complex infection and cytomegalovirus disease in patients with AIDS. AIDS 2000;14:2593-6.
2. Bowen EF, Wilson P, Atkins M, Madge S, Griffiths PD, Johnson MA, et al. Natural history of untreated cytomegalovirus retinitis. Lancet 1995;346:1671-3.
3. Palella Jr FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
4. Jacobson MA, Zegans M, Pavan PR, O'Donnell JJ, Sattler F, Rao N, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997;349:1443-5.
5. Johnson SC, Benson CA, Johnson DW, Weinberg A. Recurrences of cytomegalovirus retinitis in a human immunodeficiency virus-infected patient, despite potent antiretroviral therapy and apparent immune reconstitution. Clin Infect Dis 2001;32:815-9.
6. Mallolas J, Arrizabalaga J, Lonca M, Gatell JM, Adan A, Martinez-Chamorro E, et al. Cytomegalovirus disease in HIV-1-infected patients treated with protease inhibitors. AIDS 1997;11:1785-7.
7. Michelet C, Arvieux C, Francois C, Besnier JM, Rogez JP, Breux JP, et al. Opportunistic infections occurring during highly active antiretroviral treatment. AIDS 1998;12:1815-22.
8. Monforte AA, Mainini F, Vago L, Magni C, Musicco M, Antinori S, et al. Factors associated with increased risk of acquiring cytomegalovirus disease in AIDS patients. J Infect Dis 1993;168:1071-2.
9. Reed JB, Morse LS. CMV retinitis and the controversies associated with highly active antiretroviral therapy and the immune recovery hypothesis. Aids Patient Care STDS 1998;12:181-5.
10. Schrier RD, Freeman WR, Wiley CA, McCutchan JA. Immune predispositions for cytomegalovirus retinitis in AIDS: The HNRC Group. J Clin Invest 1995;95: 1741-6.
11. Bini T, Testa L, Chiesa E, Adorni F, Abeli C, Castelnuovo B, et al. Outcome of a second-line protease inhibitor-containing regimen in patients failing or intolerant of a first highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000;24:115-22.
12. Raffi F, Reliquet V, Podzamczer D, Pollard RB. Efficacy of nevirapine-based haart in HIV-1-infected, treatment-naive persons with high and low baseline viral loads. HIV Clin Trials 2001;2:317-22.
13. Hoover DR, Peng Y, Saah A, Semba R, Detels RR, Rinaldo Jr. CR, et al. Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression. Arch Ophthalmol 1996;114:821-7.
14. Lyles RH, Chu C, Mellors JW, Margolick JB, Detels R, Giorgi JV, et al. Prognostic value of plasma HIV RNA in the natural history of Pneumocystis carinii pneumonia, cytomegalovirus and Mycobacterium avium complex: Multicenter AIDS Cohort Study. AIDS 1999;13:341-9.
15. Holland GN, Shuler JD. Progression rates of cytomegalovirus retinopathy in ganciclovir-treated and untreated patients. Arch Ophthalmol 1992;110:1435-42.
16. Migdal C. Funduscopy versus photographic assessment of cytomegalovirus retinitis progression: A clinician's perspective. AIDS 1996;10(suppl 4):S19-23.
17. Holland GN, Buhles Jr. WC, Mastre B, Kaplan HJ. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy: Use of a standardized system for the assessment of disease outcome: UCLA CMV Retinopathy. Study Group. Arch Ophthalmol 1989;107:1759-66.
18. Cheng L, Rao NA, Keefe KS, Avila Jr CP, Macdonald JC, Freeman WR. Cytomegalovirus iritis. Ophthalmic Surg Lasers 1998;29:930-2.
19. Spaide RF, Vitale AT, Toth IR, Oliver JM. Frosted branch angiitis associated with cytomegalovirus retinitis. Am J Ophthalmol 1992;113:522-8.
20. Biswas J, Raizada S, Gopal L, Kumarasamy, N, Solomon S. Bilateral frosted branch angiitis and cytomegalovirus retinitis in acquired immunodeficiency syndrome. Indian J Ophthalmol 1999;47:195-7.
21. Ho M. Epidemiology of cytomegalovirus infections. Rev Infect Dis 1990;12(suppl 7):S701-10.
22. Merigan TC, Resta S. Cytomegalovirus: Where have we been and where are we going? Rev Infect Dis 1990;12(suppl 7):S693-700.
23. Rao NA, Zhang J, Ishimoto S. Role of retinal vascular endothelial cells in development of CMV retinitis. Trans Am Ophthalmol Soc 1998;96:111-23.
24. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998;338:1741-51.
25. Mutimer D. CMV infection of transplant recipients. J Hepatol 1996;25:259-69.
26. Goodgame RW. Gastrointestinal cytomegalovirus disease. Ann Intern Med 1993;119:924-35.
27. Marks SC, Upadhyay S, Crane L. Cytomegalovirus sinusitis: A new manifestation of AIDS. Arch Otolaryngol Head Neck Surg 1996;122:789-91.
28. Sadler M, Nelson M. Peripheral neuropathy in HIV. Int J STD AIDS 1997;8:16-21; quiz 22.
29. Zaia JA. Epidemiology and pathogenesis of cytomegalovirus disease. Semin Hematol 1990;27:5-10; discussion 28-19.
30. Anders HJ, Goebel FD. Neurological manifestations of cytomegalovirus infection in the acquired immunodeficiency syndrome. Int J STD AIDS 1999;10:151-9; quiz 160-151.
31. Martin DF, Dunn JP, Davis JL, Duker JS, Engstrom Jr RE, Friedberg DN, et al. Use of the ganciclovir implant for the treatment of cytomegalovirus retinitis in the era of potent antiretroviral therapy: Recommendations of the International AIDS Society-USA panel. Am J Ophthalmol 1999;127:329-39.
32. Musch DC, Martin DF, Gordon JF, Davis MD, Kuppermann BD. Treatment ofcytomegalovirus retinitis with a sustained-release ganciclovir implant: The Ganciclovir Implant Study Group. N Engl J Med 1997;337:83-90.
33. Smith TJ, Pearson PA, Blandford DL, Brown JD, Goins KA, Hollins JL, et al. Intravitreal sustained-release ganciclovir. Arch Ophthalmol 1992;110:255-8.
34. Freeman WR, Henderly DE, Wan WL, Causey D, Trousdale M, Green RL, et al. Prevalence, pathophysiology, and treatment of rhegmatogenous retinal detachment in treated cytomegalovirus retinitis. Am J Ophthalmol 1987;103:527-36.
35. Jabs DA, Enger C, Haller J, de Bustros S. Retinal detachments in patients with cytomegalovirus retinitis. Arch Ophthalmol 1991;109:794-9.
36. Lim JI, Wolitz RA, Dowling AH, Bloom HR, Irvine AR, Schwartz DM. Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 1999; 127:288-93.
37. Martin DF, Kuppermann BD, Wolitz RA, Palestine C, Robinson C. Anonymous. Combined oral ganciclovir (GCV) and intravitreal GCV implant for treatment of patients with cytomegalovirus (CMV) retinitis: a randomized, controlled study [abstract LB-9]. In: Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1997, Toronto, Ontario.
38. Anonymous. Cytomegalovirus (CMV) culture results, drug resistance, and clinical outcome in patients with AIDS and CMV retinitis treated with foscamet or ganciclovir: Studies of ocular complications of AIDS (SOCA) in collaboration with the AIDS Clinical Trial Group. J Infect Dis 1997;176:50-8.
39. Baudouin C, Chassain C, Caujolle C, Gastaud P. Treatment of cytomegalovirus retinitis in AIDS patients using intravitreal injections of highly concentrated ganciclovir. Ophthalmologica 1996;210:329-35.
40. Desatnik HR, Foster RE, Lowder CY. Treatment of clinically resistant cytomegalovirus retinitis with combined intravitreal injections of ganciclovir and foscarnet. Am J Ophthalmol 1996;122:121-3.
41. Guembel HO, Hofmann F, van Even G, Cinatl J, Makabe R. Therapy with a combination of intravitreal foscamet and intravenous ganciclovir in clinically resistant cytomegalovirus retinitis and patients with acquired immunodeficiency syndrome. Ger J Ophthalmol 1996;5:490-1.
42. Montero MC, Pastor M, Buenestado C, Lluch A, Atienza M. Intravitreal ganciclovir for cytomegalovirus retinitis in patients with AIDS. Ann Pharmacother 1996;30:717-23.
43. Morlet N, Young S, Naidoo D, Graham G, Coroneo MT. High dose intravitreal ganciclovir injection provides a prolonged therapeutic intraocular concentration. Br J Ophthalmol 1996;80:214-6.
44. Lalezari JP, Holland GN, Kramer F, McKinley GF, Kemper CA, Ives DV, et al. Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:339-44.
45. Davis JL, Taskintuna I, Freeman WR, Weinberg DV, Feuer WJ, Leonard RE. Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis. Arch Ophthalmol 1997;115:733-7.
46. Anonymous. The ganciclovir implant plus oral ganciclovir versus parenteral cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: The Ganciclovir Cidofovir Cytomegalovirus Retinitis Trial. Am J Ophthalmol 2001;131:457-67.
47. Hoffman VF, Skiest DJ. Therapeutic developments in cytomegalovirus retinitis. Expert Opin Investig Drugs 2000;9:207-20.
48. Anonymous. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS; the Cytomegalovirus Retreatment Trial: The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Arch Ophthalmol 1996;114:23-33.
49. Whitley RJ, Jacobson MA, Friedberg DN, Holland GN, Jabs DA, Dieterich DT, et al. Guidelines for the treatment ofcytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: Recommendations of an international panel: International AIDS Society-USA. Arch Intern Med 1998;158:957-69.
50. Orr RM. Technology evaluation: Fomivirsen, Isis Pharmaceuticals Inc/CIBA vision. Curr Opin Mol Ther 2001;3:288-94.
51. Jabs DA, Bolton SG, Dunn JP, Palestine AG. Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy. Am J Ophthalmol 1998;126:817-22.
52. Jouan M, Saves M, Tubiana R, Carcelain G, Cassoux N, Aubron-Olivier C, et al. Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 2001;15:23-31.
53. Whitcup SM, Fortin E, Lindblad AS, Griffiths P, Metcalf JA, Robinson MR, et al. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. JAMA 1999; 282:1633-7.
54. Zambarakji HJ, Newson RB, Mitchell SM. CMVR diagnoses and progression of CD4 cell counts and HIV viral load measurements in HIV patients on HAART. Br J Ophthalmol 2001;85:837-41.
55. Manfredi R, Chiodo F. Limits of deep salvage antiretroviral therapy with nelfinavir plus either efavirenz or nevirapine, in highly pre-treated patients with HIV disease. Int J Antimicrob Agents 2001;17:511-6.
56. Nunez M, Soriano V. Salvage therapy for HIV infection: When and how. Aids Patient Care STDS 2000; 14:465-76.
57. Youle M. Salvage treatment in HIV disease. Int J STD AIDS 2001;12:286-94.
58. Song MK, Karavellas MP, MacDonald JC, Plummer DJ, Freeman WR. Characterization of reactivation of cytomegalovirus retinitis in patients healed after treatment with highly active antiretroviral therapy. Retina 2000;20:151-5.
59. Torriani FJ, Freeman WR, Macdonald JC, Karavellas MP, Durand DM, Jeffrey DD, et al. CMV retinitis recurs after stopping treatment in virological and immunological failures of potent antiretroviral therapy. AIDS 2000;14:173-80.
60. Komanduri KV, Feinberg J, Hutchins RK, Frame RD, Schmidt DK, Viswanathan MN, et al. Loss of cytomegalovirus-specific CD4+ T cell responses in human immunodeficiency virus type 1-infected patients with high CD4+ T cell counts and recurrent retinitis. J Infect Dis 2001;183:1285-9.
61. Karavellas MP, Lowder CY, Macdonald C, Avila Jr. CP, Freeman WR. Immune recovery vitritis associated with inactive cytomegalovirus retinitis: A new syndrome. Arch Ophthalmol 1998;116:169-75.
62. Robinson MR, Reed G, Csaky KG, Polis MA, Whitcup SM. Immune-recovery uveitis in patients with cytomegalovirus retinitis taking highly active antiretroviral therapy. Am J Ophthalmol 2000;130:49-56.
63. Henderson HW, Mitchell SM. Treatment of immune recovery vitritis with local steroids. Br J Ophthalmol 1999;83:540-5.
64. Canzano JC, Reed JB, Morse LS. Vitreomacular traction syndrome following highly active antiretroviral therapy in AIDS patients with cytomegalovirus retinitis. Retina 1998;18:443-7.
65. Zegans ME, Walton RC, Holland GN, O'Donnell JJ, Jacobson MA, Margolis TP. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 1998;125: 292-300.
66. Kuppermann BD, Holland GN. Immune recovery uveitis. Am J Ophthalmol 2000;130:103-6.